<doc>
  <docmeta id="113hr4771rh">
    <bill congress="113" type="hr" number="4771" version="rh"/>
    <revision size="29627" annotations="0" status="complete" id="12" commit-time="2014-10-15T15:23:37Z" committer="mbohmer" doc="113hr4771rh/12.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Reported-in-House" bill-type="olc" dms-id="H64262D40BC88475CB7B3772A22FF4AC9" public-private="public"> 
<metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 HR 4771 RH: Designer Anabolic Steroid Control Act of 2014</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. House of Representatives</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2014-09-15</dc:date>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">IB</distribution-code> 
<calendar display="yes">Union Calendar No. 434</calendar>
<congress display="yes">113th CONGRESS</congress> <session display="yes">2d Session</session> 
<legis-num>H. R. 4771</legis-num>
<associated-doc role="report" display="yes">[Report No. 113–587, Parts I and II]</associated-doc> 
<current-chamber display="yes">IN THE HOUSE OF REPRESENTATIVES</current-chamber> 
<action> 
<action-date date="20140529">May 29, 2014</action-date> 
<action-desc>
        <sponsor name-id="P000373">Mr. Pitts</sponsor> (for himself and <cosponsor name-id="P000034">Mr. Pallone</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00" added-display-style="italic" deleted-display-style="strikethrough">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on the <committee-name committee-id="HJU00">Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc> 
</action> 
<action>
<action-date date="20140915">September 15, 2014</action-date>
<action-desc>Additional sponsors: <cosponsor name-id="C001076">Mr. Chaffetz</cosponsor>, <cosponsor name-id="L000570">Mr. Ben Ray Luján of New Mexico</cosponsor>, <cosponsor name-id="S001170">Ms. Shea-Porter</cosponsor>, <cosponsor name-id="A000369">Mr. Amodei</cosponsor>, and <cosponsor name-id="D000622">Ms. Duckworth</cosponsor>
      </action-desc>
</action>
<action>
<action-date date="20140915">September 15, 2014</action-date>
<action-desc>Reported from the Committee on <committee-name committee-id="HIF00" added-display-style="italic" deleted-display-style="strikethrough">Energy and Commerce</committee-name> with an amendment</action-desc>
<action-instruction>Strike out all after the enacting clause and insert the part printed in italic</action-instruction> 
</action>
<action>
<action-date date="20140915">September 15, 2014</action-date>
<action-desc>Reported from the <committee-name committee-id="HJU00">Committee on the Judiciary</committee-name> with an amendment; committed to the Committee of the Whole House on the State of the Union and ordered to be printed</action-desc>
<action-instruction>Strike out all after the enacting clause and insert the part printed in boldface roman</action-instruction>
<action-instruction>For text of introduced bill, see copy of bill as introduced on May 29, 2014</action-instruction>
</action>
<action display="yes">
<action-desc display="yes">
        <pagebreak/>
      </action-desc>
</action>
<legis-type>A BILL</legis-type> 
<official-title display="yes">To amend the Controlled Substances Act to more effectively regulate anabolic steroids.<pagebreak/>
    </official-title> 
</form> 
<legis-body display-enacting-clause="yes-display-enacting-clause" changed="added" style="OLC" committee-id="HIF00" reported-display-style="italic" id="H4D76B38E58454029A775CE8A90373DAF">
<section id="HB8B120A7C0FA40F4B0DE071D84E421D5" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the <quote>
          <short-title>
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" entity-type="act" value="Designer Anabolic Steroid Control Act of 2014">Designer Anabolic Steroid Control Act of 2014</cato:entity-ref>
          </short-title>
        </quote>.</text>
    </section>
<section id="H189FECF638EB445BB34865FDE8B09B67">
      <enum>2.</enum>
      <header>Amendments to the Controlled Substances Act</header>
<subsection id="HC4170E83FFED4C348DEAADBAD2479AE0">
        <enum>(a)</enum>
        <header>Definitions</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:102/p:41">Section 102(41) of the Controlled Substances Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/802">
            <cato:entity-ref entity-type="uscode" value="usc/21/802/41">21 U.S.C. 802(41)</cato:entity-ref>
          </external-xref>)</cato:entity> is amended—</text>
<paragraph id="H303650BA518C481C8DD277BB774822B3">
          <enum>(1)</enum>
          <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A">subparagraph (A)</cato:entity-ref>—</text>
<subparagraph id="H9AB0A43179164A43AD7D1E7AC6F1CB51">
            <enum>(A)</enum>
            <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/p:41/sp:A/cl:xlix" entity-type="act">clause (xlix)</cato:entity-ref>, by striking <quote>and</quote> at the end;</text>
          </subparagraph>
<subparagraph id="HEE50B467F3044B78A4AAB2681B016135">
            <enum>(B)</enum>
            <text>by redesignating <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/p:41/sp:A/cl:xlx" entity-type="act">clause (xlx)</cato:entity-ref> as <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Controlled Substances Act/s:102/p:41/sp:A/cl:lxxv" entity-type="act">clause (lxxv)</cato:entity-ref>; and</text>
          </subparagraph>
<subparagraph id="HAEB4C71A9F8F494F9493950B9739F742">
            <enum>(C)</enum>
            <text>by inserting after <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/p:41/sp:A/cl:xlix" entity-type="act">clause (xlix)</cato:entity-ref> the following:</text>
<quoted-block display-inline="no-display-inline" id="HD051B9C5B7344CB4B017588F7659D47C" style="OLC">
<clause id="H20145617058F4BF49BD1A7411FE79E30" indent="paragraph">
                <enum>(l)</enum>
                <text>5α-Androstan-3,6,17-trione;</text>
              </clause>
<clause id="H6439D3337CFD4741B5121BE8E0C50748" indent="paragraph">
                <enum>(li)</enum>
                <text>6-bromo-androstan-3,17-dione;</text>
              </clause>
<clause id="HA3EA4DF57B7A48309B43B5D213E0B03B" indent="paragraph">
                <enum>(lii)</enum>
                <text>6-bromo-androsta-1,4-diene-3,17-dione;</text>
              </clause>
<clause id="H8007CFC696844591B04CAF60BD317D8E" indent="paragraph">
                <enum>(liii)</enum>
                <text>4-chloro-17α-methyl-androsta-1,4-diene-3,17β-diol;</text>
              </clause>
<clause id="H044449C78833439DB446E364BFC463A2" indent="paragraph">
                <enum>(liv)</enum>
                <text>4-chloro-17α-methyl-androst-4-ene-3β,17β-diol;</text>
              </clause>
<clause id="H3249219F8FE44DC4AB8F1DB24E607971" indent="paragraph">
                <enum>(lv)</enum>
                <text>4-chloro-17α-methyl-17β-hydroxy-androst-4-en-3-one;</text>
              </clause>
<clause id="H11390C77C920440D86EEB1D8FCDC82F3" indent="paragraph">
                <enum>(lvi)</enum>
                <text>4-chloro-17α-methyl-17β-hydroxy-androst-4-ene-3,11-dione;</text>
              </clause>
<clause id="H1D44CE1A047B49DB91EA8AA0737D72DD" indent="paragraph">
                <enum>(lvii)</enum>
                <text>4-chloro-17α-methyl-androsta-1,4-diene-3,17β-diol;</text>
              </clause>
<clause id="H46041FB2D1BB48B0A5356365F44A2DB2" indent="paragraph">
                <enum>(lviii)</enum>
                <text>2α,17α-dimethyl-17β-hydroxy-5α-androstan-3-one;</text>
              </clause>
<clause id="HCC4AFB4A624A4BECB4F1A78AA41DD460" indent="paragraph">
                <enum>(lix)</enum>
                <text>2α,17α-dimethyl-17β-hydroxy-5β-androstan-3-one;</text>
              </clause>
<clause id="HF2DE1198C0504321960860A82CB79325" indent="paragraph">
                <enum>(lx)</enum>
                <text>2α,3α-epithio-17α-methyl-5α-androstan-17β-ol;</text>
              </clause>
<clause id="HCFC6CB42450044EDABC1015D6A4C41C5" indent="paragraph">
                <enum>(lxi)</enum>
                <text>[3,2-c]-furazan-5α-androstan-17β-ol;</text>
              </clause>
<clause id="H6FC6D3B3037B4D7F898B32E1D574B9C8" indent="paragraph">
                <enum>(lxii)</enum>
                <text>3β-hydroxy-estra-4,9,11-trien-17-one;</text>
              </clause>
<clause id="H5F697C776C414D69B30C421B355148FF" indent="paragraph">
                <enum>(lxiii)</enum>
                <text>17α-methyl-androst-2-ene-3,17β-diol;</text>
              </clause>
<clause id="H6CF859162C924256B9D180B7AD55353E" indent="paragraph">
                <enum>(lxiv)</enum>
                <text>17α-methyl-androsta-1,4-diene-3,17β-diol;</text>
              </clause>
<clause id="HD8B1BAC98F084DE79F1AF3D322ABAA06" indent="paragraph">
                <enum>(lxv)</enum>
                <text>Estra-4,9,11-triene-3,17-dione;</text>
              </clause>
<clause id="H58B96893C85D48EE85703A3C0404A136" indent="paragraph">
                <enum>(lxvi)</enum>
                <text>18a-Homo-3-hydroxy-estra-2,5(10)-dien-17-one;</text>
              </clause>
<clause id="H662144FE5B474D4F9D666105AD86CE30" indent="paragraph">
                <enum>(lxvii)</enum>
                <text>6α-Methyl-androst-4-ene-3,17-dione;</text>
              </clause>
<clause id="H1C270B01F2434896AEB96D70E9DE2C75" indent="paragraph">
                <enum>(lxviii)</enum>
                <text>17α-Methyl-androstan-3-hydroxyimine-17β-ol;</text>
              </clause>
<clause id="H5E7748D4943E45D89D4848B1E5C20536" indent="paragraph">
                <enum>(lxix)</enum>
                <text>17α-Methyl-5α-androstan-17β-ol;</text>
              </clause>
<clause id="HB2B43A41B3124052A84ADA3372D794DC" indent="paragraph">
                <enum>(lxx)</enum>
                <text>17β-Hydroxy-androstano[2,3-d]isoxazole;</text>
              </clause>
<clause id="H5721A09526934FD7A40BB3B1E2C5BCF6" indent="paragraph">
                <enum>(lxxi)</enum>
                <text>17β-Hydroxy-androstano[3,2-c]isoxazole;</text>
              </clause>
<clause id="H42242DBC13B5408EB795EA30CF060263" indent="paragraph">
                <enum>(lxxii)</enum>
                <text>4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole-5α-androstan-17β-ol;</text>
              </clause>
<clause commented="no" display-inline="no-display-inline" id="H4B235E54A9C74704A84FD4CAC4922EF0" indent="paragraph">
                <enum>(lxxiii)</enum>
                <text>[3,2-c]pyrazole-androst-4-en-17β-ol;</text>
              </clause>
<clause id="H2F86FE9F8444451B980FD98A3F24C46A" indent="paragraph">
                <enum>(lxxiv)</enum>
                <text>[3,2-c]pyrazole-5α-androstan-17β-ol; and</text>
              </clause>
              <after-quoted-block>; and</after-quoted-block>
            </quoted-block>
          </subparagraph>
        </paragraph>
<paragraph id="H8DFE92665CE641259F2BAEA838943EC8">
          <enum>(2)</enum>
          <text>by adding at the end the following:</text>
<quoted-block display-inline="no-display-inline" id="H8B94346A26594536BBC0ACCEC73FDBEF" style="OLC">
<subparagraph id="H077BD6BC69BC492B8F084E6B26636F62" indent="paragraph">
              <enum>(C)</enum>
<clause commented="no" display-inline="yes-display-inline" id="HAB207834502F41648003584BC9C2008D">
                <enum>(i)</enum>
                <text>Subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/p:41/sp:C/cl:ii" entity-type="act" proposed="true">clause (ii)</cato:entity-ref>, a drug or hormonal substance (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone) that is not listed in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/p:41/sp:A" entity-type="act">subparagraph (A)</cato:entity-ref> and is derived from, or has a chemical structure substantially similar to, 1 or more anabolic steroids listed in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/p:41/sp:A" entity-type="act">subparagraph (A)</cato:entity-ref> shall be considered to be an anabolic steroid for purposes of this Act if—</text>
<subclause id="HBA22839FB69D4E1696444121E64CE88A" indent="subparagraph">
                  <enum>(I)</enum>
                  <text>the drug or substance has been created or manufactured with the intent of producing a drug or other substance that either—</text>
<item id="H3AACCF12E7C745F18AD10D46B1ECF4FE" indent="clause">
                    <enum>(aa)</enum>
                    <text>promotes muscle growth; or</text>
                  </item>
<item id="HEC9D1D55DF3847FABC2CF0E3867F0E03" indent="clause">
                    <enum>(bb)</enum>
                    <text>otherwise causes a pharmacological effect similar to that of testosterone; or</text>
                  </item>
                </subclause>
<subclause id="HF81243E4A9914020935A3EADB17D092B" indent="subparagraph">
                  <enum>(II)</enum>
                  <text>the drug or substance has been, or is intended to be, marketed or otherwise promoted in any manner suggesting that consuming it will promote muscle growth or any other pharmacological effect similar to that of testosterone.</text>
                </subclause>
              </clause>
<clause id="H2BB4D63C842F43068E18D410B4E4D933" indent="paragraph">
                <enum>(ii)</enum>
                <text>A substance shall not be considered to be a drug or hormonal substance for purposes of this subparagraph if it—</text>
<subclause id="H6C639530015C456993DFA3E959F1F792" indent="subparagraph">
                  <enum>(I)</enum>
                  <text>is—</text>
<item id="H2EF2FC160B9F40989D87744251E0F21D" indent="clause">
                    <enum>(aa)</enum>
                    <text>an herb or other botanical;</text>
                  </item>
<item id="H2BA4A305A745475DAC38ED1877A5F89F" indent="clause">
                    <enum>(bb)</enum>
                    <text>a concentrate, metabolite, or extract of, or a constituent isolated directly from, an herb or other botanical; or</text>
                  </item>
<item id="HC6ED9EE91D034BE1BF4DF648EE55831F" indent="clause">
                    <enum>(cc)</enum>
                    <text>a combination of 2 or more substances described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Controlled Substances Act/s:102/p:41/sp:C/cl:ii/scl:I/i:aa" entity-type="act">item (aa)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Controlled Substances Act/s:102/p:41/sp:C/cl:ii/scl:I/i:bb" entity-type="act">(bb)</cato:entity-ref>;</text>
                  </item>
                </subclause>
<subclause id="HCC10942380944F439A699CABB42016BB" indent="subparagraph">
                  <enum>(II)</enum>
                  <text>is a dietary ingredient for purposes of the <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                      <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act">Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/301">
                      <cato:entity-ref entity-type="uscode" value="usc/21/301/etseq">21 U.S.C. 301 et seq.</cato:entity-ref>
                    </external-xref>)</cato:entity>; and</text>
                </subclause>
<subclause id="H17EB67DA1B4A4E4BA5080BF3474C63AD" indent="subparagraph">
                  <enum>(III)</enum>
                  <text display-inline="yes-display-inline">is not anabolic or androgenic.</text>
                </subclause>
              </clause>
<clause id="HCA3202286FDC41C2A50FF9064621E9D2" indent="paragraph">
                <enum>(iii)</enum>
                <text>In accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:515/ss:a" entity-type="act">section 515(a)</cato:entity-ref>, any person claiming the benefit of an exemption or exception under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Controlled Substances Act/s:102/p:41/sp:C/cl:ii" entity-type="act">clause (ii)</cato:entity-ref> shall bear the burden of going forward with the evidence with respect to such exemption or exception.</text>
              </clause>
            </subparagraph>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
        </paragraph>
      </subsection>
<subsection id="HBBAB2857C63B448596AFA1441FE976EA">
        <enum>(b)</enum>
        <header>Classification authority</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:201">Section 201 of the Controlled Substances Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/811">
            <cato:entity-ref entity-type="uscode" value="usc/21/811">21 U.S.C. 811</cato:entity-ref>
          </external-xref>)</cato:entity> is amended by adding at the end the following:</text>
<quoted-block display-inline="no-display-inline" id="H210BF3F319C5443AB27500AB4FF00A3F" style="OLC">
<subsection id="H58350DF488944E62BABADF68BD8A2F01">
            <enum>(i)</enum>
            <header>Temporary and permanent scheduling of recently emerged anabolic steroids</header>
<paragraph id="H9468C38D96EC495184C76BC23A6B410C">
              <enum>(1)</enum>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> may issue a temporary order adding a drug or other substance to the definition of anabolic steroids if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> finds that—</text>
<subparagraph id="H15C6FB20F9A64090A695F0FDD109E936">
                <enum>(A)</enum>
                <text>the drug or other substance satisfies the criteria for being considered an anabolic steroid under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/p:41" entity-type="act">section 102(41)</cato:entity-ref> but is not listed in that section or by regulation of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> as being an anabolic steroid; and</text>
              </subparagraph>
<subparagraph id="H6761A8ABB3674FE9BB77B3AE91EA0AD1">
                <enum>(B)</enum>
                <text display-inline="yes-display-inline">adding such drug or other substance to the definition of anabolic steroids will assist in preventing abuse or misuse of the drug or other substance.</text>
              </subparagraph>
            </paragraph>
<paragraph id="H149F2DF3AB404EBAA9A51D2AE8C4A061">
              <enum>(2)</enum>
              <text>An order issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:201/ss:i/p:1" entity-type="act" proposed="true">paragraph (1)</cato:entity-ref> shall not take effect until 30 days after the date of the publication by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> of a notice in the Federal Register of the intention to issue such order and the grounds upon which such order is to be issued. The order shall expire not later than 24 months after the date it becomes effective, except that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> may, during the pendency of proceedings under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:201/ss:i/p:6" entity-type="act" proposed="true">paragraph (6)</cato:entity-ref>, extend the temporary scheduling order for up to 6 months.</text>
            </paragraph>
<paragraph id="HD1124F4D1AA743DB933742DEE21E5000">
              <enum>(3)</enum>
              <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> shall transmit notice of an order proposed to be issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:201/ss:i/p:1" entity-type="act" proposed="true">paragraph (1)</cato:entity-ref> to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7500" entity-type="federal-body">Secretary of Health and Human Services</cato:entity-ref>. In issuing an order under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:201/ss:i/p:1" entity-type="act" proposed="true">paragraph (1)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> shall take into consideration any comments submitted by the Secretary in response to a notice transmitted pursuant to this paragraph.</text>
            </paragraph>
<paragraph id="H4019B4D31A9844B2A09C5D16462E82D4">
              <enum>(4)</enum>
              <text>A temporary scheduling order issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:201/ss:i/p:1" entity-type="act" proposed="true">paragraph (1)</cato:entity-ref> shall be vacated upon the issuance of a permanent scheduling order under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:201/ss:i/p:6" entity-type="act" proposed="true">paragraph (6)</cato:entity-ref>.</text>
            </paragraph>
<paragraph id="HF7847FE8E58747A8B726E1831E8D1B74">
              <enum>(5)</enum>
              <text>An order issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:201/ss:i/p:1" entity-type="act" proposed="true">paragraph (1)</cato:entity-ref> is not subject to judicial review.</text>
            </paragraph>
<paragraph id="HED09590B30334F289B7D69ABDFE1E806">
              <enum>(6)</enum>
              <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> may, by rule, issue a permanent order adding a drug or other substance to the definition of anabolic steroids if such drug or other substance satisfies the criteria for being considered an anabolic steroid under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/p:41" entity-type="act">section 102(41)</cato:entity-ref>. Such rulemaking may be commenced simultaneously with the issuance of the temporary order issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:201/ss:i/p:1" entity-type="act" proposed="true">paragraph (1)</cato:entity-ref>.</text>
            </paragraph>
          </subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
      </subsection>
<subsection id="H53D60F480A7341A2972F13DA36A3EF99">
        <enum>(c)</enum>
        <header>Labeling requirements</header>
<paragraph id="HB53DF7718A82494EB0E17B2A583C4DB2">
          <enum>(1)</enum>
          <header>In general</header>
          <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act">Controlled Substances Act</cato:entity-ref> is amended by inserting after <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:305">section 305</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/825">
              <cato:entity-ref entity-type="uscode" value="usc/21/825">21 U.S.C. 825</cato:entity-ref>
            </external-xref>)</cato:entity> the following:</text>
<quoted-block display-inline="no-display-inline" id="H4D5E90C98EC24517BF57254B02ED580F" style="OLC">
<section id="HFF54F889ACF44A7D88BEA5BD17240E68">
              <enum>305A.</enum>
              <header>Offenses involving false labeling of anabolic steroids</header>
<subsection id="HAC93E8F5A63948DE8ECA886B14BA9B5E">
                <enum>(a)</enum>
                <header>Unlawful acts</header>
<paragraph id="HE407646D58B04451A7C03EC6779B1F4E">
                  <enum>(1)</enum>
                  <text>It shall be unlawful—</text>
<subparagraph id="H774AE438212E460E9DA65A1A9DCAAD14">
                    <enum>(A)</enum>
                    <text>to import into the United States or to export from the United States;</text>
                  </subparagraph>
<subparagraph id="HE8A3669A1438431091D9C131DFC8389E">
                    <enum>(B)</enum>
                    <text>to manufacture, distribute, dispense, sell, or offer to sell; or</text>
                  </subparagraph>
<subparagraph id="HBA2EC44F328042F886362EE689140087">
                    <enum>(C)</enum>
                    <text>to possess with intent to manufacture, distribute, dispense, sell, or offer to sell;</text>
                  </subparagraph>
                  <continuation-text continuation-text-level="paragraph">any anabolic steroid, or any product containing an anabolic steroid, that does not bear a label clearly identifying any anabolic steroid contained in such steroid or product by the nomenclature used by the International Union of Pure and Applied Chemistry (IUPAC).</continuation-text>
                </paragraph>
<paragraph id="HEB08818B11CD4AF5BACD61A51ACFD911">
                  <enum>(2)</enum>
<subparagraph id="H7F0D377D9A6D4BCFA748CB02E5078408" display-inline="yes-display-inline">
                    <enum>(A)</enum>
                    <text display-inline="yes-display-inline">A product described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Controlled Substances Act/s:305A/ss:a/p:2/sp:B" entity-type="act">subparagraph (B)</cato:entity-ref> is exempt from the International Union of Pure and Applied Chemistry nomenclature requirement of this subsection if such product is labeled in the manner required under the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act">Federal Food, Drug, and Cosmetic Act</cato:entity-ref>.</text>
                  </subparagraph>
<subparagraph id="H67AD588A5CC94FE4A82CB21FA3A8FB86" indent="up1">
                    <enum>(B)</enum>
                    <text>A product is described in this subparagraph if the product—</text>
<clause id="H74299C5F73E940C19BB2A7C68A6D5929">
                      <enum>(i)</enum>
                      <text>is the subject of an approved application as described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:b" entity-type="act">section 505(b)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j" entity-type="act">(j) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>; or</text>
                    </clause>
<clause id="H58F1F62223CF49CA9D16F6291EAC60B1">
                      <enum>(ii)</enum>
                      <text>is exempt from the provisions of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Federal Food, Drug, and Cosmetic Act/s:505" entity-type="act">section 505</cato:entity-ref> of such Act relating to new drugs because—</text>
<subclause id="H65CB067BBC2C4CBAB83A8426DCF85C86">
                        <enum>(I)</enum>
                        <text>it is intended solely for investigational use as described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:i" entity-type="act">section 505(i)</cato:entity-ref> of such Act; and</text>
                      </subclause>
<subclause id="H0D6026AA099E48E6837D78923C198B0D">
                        <enum>(II)</enum>
                        <text>such product is being used exclusively for purposes of a clinical trial that is the subject of an effective investigational new drug application.</text>
                      </subclause>
                    </clause>
                  </subparagraph>
                </paragraph>
              </subsection>
<subsection id="H9CDE5447F2C9457CACD8FAF98ED3626B">
                <enum>(b)</enum>
                <header>Criminal penalties</header>
                <text>Any person who violates <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:305A/ss:a" entity-type="act" proposed="true">subsection (a)</cato:entity-ref> knowing, intending, or having reasonable cause to believe, that the substance or product is an anabolic steroid, or contains an anabolic steroid, shall be sentenced to a term of imprisonment of not more than 10 years, a fine not to exceed the greater of that authorized in accordance with the provisions of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="usc/18" entity-type="uscode">title 18, United States Code</cato:entity-ref>, or $500,000 if the defendant is an individual or $2,500,000 if the defendant is other than an individual, or both.</text>
              </subsection>
<subsection id="HA059AEFC2C5647AF96B87F1DEA54D89A">
                <enum>(c)</enum>
                <header>Civil penalties</header>
<paragraph id="HFD46C43C608B46759B35EBE5115A4AE3">
                  <enum>(1)</enum>
                  <text>Any person who violates <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:305A/ss:a" entity-type="act" proposed="true">subsection (a)</cato:entity-ref> shall be subject to a civil penalty as follows:</text>
<subparagraph id="HF39ECE2582334D97AF6C64DEA44ECC29">
                    <enum>(A)</enum>
                    <text>In the case of an importer, exporter, manufacturer, or distributor (other than as provided in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Controlled Substances Act/s:305A/ss:c/p:1/sp:B" entity-type="act">subparagraph (B)</cato:entity-ref>), up to $500,000 per violation. For purposes of this subparagraph, a violation is defined as each instance of importation, exportation, manufacturing, or distribution, and each anabolic steroid or product imported, exported, manufactured, or distributed.</text>
                  </subparagraph>
<subparagraph id="H5138A7B9B65F4B4C868020967F330DD5">
                    <enum>(B)</enum>
                    <text>In the case of a sale or offer to sell at retail, up to $25,000 per violation. For purposes of this subparagraph, each sale and each product offered for sale shall be considered a separate violation. Continued offers to sell by a person 10 or more days after written notice (including through electronic message) to the person by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> or the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7500" entity-type="federal-body">Secretary</cato:entity-ref> shall be considered additional violations.</text>
                  </subparagraph>
                </paragraph>
<paragraph id="HB69585AA2DD0473EAD88FE44BF0E468D">
                  <enum>(2)</enum>
                  <text>In this subsection, the term <term>product</term> means a discrete article, either in bulk or in finished form prepared for sale. A number of articles, if similarly packaged and bearing identical labels, shall be considered as one product, but each package size, form, or differently labeled article shall be considered a separate product.</text>
                </paragraph>
              </subsection>
<subsection id="H514C2C9ADBEC4D09A1B69571A0715F5A">
                <enum>(d)</enum>
                <header>Identification and publication of list of products containing anabolic steroids</header>
<paragraph id="H89D48C139BC74F968E1D43B6067071A4">
                  <enum>(1)</enum>
                  <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> may, in his discretion, collect data and analyze products to determine whether they contain anabolic steroids and are properly labeled in accordance with this section. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> may publish in the Federal Register or on the website of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1524" entity-type="federal-body">Drug Enforcement Administration</cato:entity-ref> a list of products that he has determined, based on substantial evidence, contain an anabolic steroid and are not labeled in accordance with this section.</text>
                </paragraph>
<paragraph id="H9E91396AEA1F4A478B75A1D55611C9A8">
                  <enum>(2)</enum>
                  <text>The absence of a product from the list referred to in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:305A/ss:d/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall not constitute evidence that the product does not contain an anabolic steroid.</text>
                </paragraph>
              </subsection>
            </section>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
        </paragraph>
<paragraph id="H0598F3EB55DB40138E41C6922565B319">
          <enum>(2)</enum>
          <header>Table of contents</header>
          <text>The table of contents for the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Comprehensive Drug Abuse Prevention and Control Act of 1970">Comprehensive Drug Abuse Prevention and Control Act of 1970</cato:entity-ref> is amended by inserting after the item relating to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Comprehensive Drug Abuse Prevention and Control Act of 1970/s:305">section 305</cato:entity-ref> the following:</text>
<quoted-block display-inline="no-display-inline" id="HF969878EDF7F4EDF89FCB9C4C8655DC1" style="OLC">
<toc>
<toc-entry bold="off" level="section">Sec. 305A. Offenses involving false labeling of anabolic steroids.</toc-entry>
            </toc>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
        </paragraph>
      </subsection>
    </section>
</legis-body> 
<legis-body display-enacting-clause="no-display-enacting-clause" changed="added" style="OLC" committee-id="HJU00" reported-display-style="boldface-roman" id="HEFB1AAE712C94DA58AA98ACF00792C01"> 
<section id="HDA55F5C4DBA443268D8DC9436C2CE230" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the <quote>
          <short-title>
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Designer Anabolic Steroid Control Act of 2014" proposed="true">Designer Anabolic Steroid Control Act of 2014</cato:entity-ref>
          </short-title>
        </quote>.</text>
    </section> 
<section id="H13BF72572A9941B4A215ACA60DE702B3">
      <enum>2.</enum>
      <header>Amendments to the Controlled Substances Act</header> 
<subsection id="H7B5A17B28267408BAA565BB19728976E">
        <enum>(a)</enum>
        <header>Definitions</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:102/p:41">Section 102(41) of the Controlled Substances Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/802">
            <cato:entity-ref entity-type="uscode" value="usc/21/802/41">21 U.S.C. 802(41)</cato:entity-ref>
          </external-xref>)</cato:entity> is amended—</text> 
<paragraph id="HADBB1B5FD2DD4EB6BD8FA4420DEDEDEF">
          <enum>(1)</enum>
          <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/p:41/sp:A" entity-type="act">subparagraph (A)</cato:entity-ref>—</text> 
<subparagraph id="H0F7FCBBE1D37466DA7711E2A6CFD4195">
            <enum>(A)</enum>
            <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/p:41/sp:A/cl:xlix" entity-type="act">clause (xlix)</cato:entity-ref>, by striking <quote>and</quote> at the end;</text>
          </subparagraph> 
<subparagraph id="H8FD186FEE86842118DF6E03DC9C15774">
            <enum>(B)</enum>
            <text>by redesignating <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/p:41/sp:A/cl:xlx" entity-type="act">clause (xlx)</cato:entity-ref> as <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Controlled Substances Act/s:102/p:41/sp:A/cl:lxxv" entity-type="act">clause (lxxv)</cato:entity-ref>; and</text>
          </subparagraph> 
<subparagraph id="H41A6CA8E13104226842119F935265BFE">
            <enum>(C)</enum>
            <text>by inserting after <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/p:41/sp:A/cl:xlix" entity-type="act">clause (xlix)</cato:entity-ref> the following:</text> 
<quoted-block style="OLC" display-inline="no-display-inline" id="HBB8C608CEA7846B399706D25220329C5"> 
<clause id="HC2321B0A79B442BFACB98905D5F3F111" indent="paragraph">
                <enum>(l)</enum>
                <text>5α-Androstan-3,6,17-trione;</text>
              </clause> 
<clause id="HE99F5D227B194F8FAD7AF853D73D0A0B" indent="paragraph">
                <enum>(li)</enum>
                <text>6-bromo-androstan-3,17-dione;</text>
              </clause> 
<clause id="H49844A96005A43EEB07460B97C89E4FB" indent="paragraph">
                <enum>(lii)</enum>
                <text>6-bromo-androsta-1,4-diene-3,17-dione;</text>
              </clause> 
<clause id="H3DFCBEC7D4E5426BBCCDCDAE3CD46248" indent="paragraph">
                <enum>(liii)</enum>
                <text>4-chloro-17α-methyl-androsta-1,4-diene-3,17β-diol;</text>
              </clause> 
<clause id="HF430FE51452C407881F3DCB1FC9CE48D" indent="paragraph">
                <enum>(liv)</enum>
                <text>4-chloro-17α-methyl-androst-4-ene-3β,17β-diol;</text>
              </clause> 
<clause id="H027127650163401FA2F09F101546FE3A" indent="paragraph">
                <enum>(lv)</enum>
                <text>4-chloro-17α-methyl-17β-hydroxy-androst-4-en-3-one;</text>
              </clause> 
<clause id="HAA0E58FEE6334535986B5933D5B2CF4B" indent="paragraph">
                <enum>(lvi)</enum>
                <text>4-chloro-17α-methyl-17β-hydroxy-androst-4-ene-3,11-dione;</text>
              </clause> 
<clause id="HBC1406CE9A5C4FF586FEFF43BD8EDAEA" indent="paragraph">
                <enum>(lvii)</enum>
                <text>4-chloro-17α-methyl-androsta-1,4-diene-3,17β-diol;</text>
              </clause> 
<clause id="HB1E278EECDB04734B4C817999C4650D9" indent="paragraph">
                <enum>(lviii)</enum>
                <text>2α,17α-dimethyl-17β-hydroxy-5α-androstan-3-one;</text>
              </clause> 
<clause id="HE16AE828C3434FC494F185CFDEB6DEBB" indent="paragraph">
                <enum>(lix)</enum>
                <text>2α,17α-dimethyl-17β-hydroxy-5β-androstan-3-one;</text>
              </clause> 
<clause id="H6AD8DC96472D487E98720E98AC5ABF60" indent="paragraph">
                <enum>(lx)</enum>
                <text>2α,3α-epithio-17α-methyl-5α-androstan-17β-ol;</text>
              </clause> 
<clause id="H4E08EDE78F9E4547BC688CAB3994D1AB" indent="paragraph">
                <enum>(lxi)</enum>
                <text>[3,2-c]-furazan-5α-androstan-17β-ol;</text>
              </clause> 
<clause id="H94A55DCAADF94E7387E9C0797F258679" indent="paragraph">
                <enum>(lxii)</enum>
                <text>3β-hydroxy-estra-4,9,11-trien-17-one;</text>
              </clause> 
<clause id="H38324C03B6EF41729E14B329D0C2DF7B" indent="paragraph">
                <enum>(lxiii)</enum>
                <text>17α-methyl-androst-2-ene-3,17β-diol;</text>
              </clause> 
<clause id="HE304CD9CFA3D4F09BEC18691958015C8" indent="paragraph">
                <enum>(lxiv)</enum>
                <text>17α-methyl-androsta-1,4-diene-3,17β-diol;</text>
              </clause> 
<clause id="HA42764977A934AFA8F57468F4C4B9925" indent="paragraph">
                <enum>(lxv)</enum>
                <text>Estra-4,9,11-triene-3,17-dione;</text>
              </clause> 
<clause id="H12E67564D6AA406ABAFBDB5017743AA5" indent="paragraph">
                <enum>(lxvi)</enum>
                <text>18a-Homo-3-hydroxy-estra-2,5(10)-dien-17-one;</text>
              </clause> 
<clause id="H0B2729B2B73C4B17AF818473087F3D4F" indent="paragraph">
                <enum>(lxvii)</enum>
                <text>6α-Methyl-androst-4-ene-3,17-dione;</text>
              </clause> 
<clause id="H047ADE4CC74440D6A3E66C1A36D042A7" indent="paragraph">
                <enum>(lxviii)</enum>
                <text>17α-Methyl-androstan-3-hydroxyimine-17β-ol;</text>
              </clause> 
<clause id="H2A6C993FA28748D19F14867A9227A109" indent="paragraph">
                <enum>(lxix)</enum>
                <text>17α-Methyl-5α-androstan-17β-ol;</text>
              </clause> 
<clause id="H5AFAF56CEE244F19B0BC2016852D3024" indent="paragraph">
                <enum>(lxx)</enum>
                <text>17β-Hydroxy-androstano[2,3-d]isoxazole;</text>
              </clause> 
<clause id="HB19E2DB229E24E5E9C548BD04BE33D34" indent="paragraph">
                <enum>(lxxi)</enum>
                <text>17β-Hydroxy-androstano[3,2-c]isoxazole;</text>
              </clause> 
<clause id="H8BC30A6213384072B0D7212BA7DC7354" indent="paragraph">
                <enum>(lxxii)</enum>
                <text>4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole-5α-androstan-17β-ol;</text>
              </clause> 
<clause id="H68186E0BFC054DC3AA0B2F2EDD68A98E" indent="paragraph" commented="no" display-inline="no-display-inline">
                <enum>(lxxiii)</enum>
                <text>[3,2-c]pyrazole-androst-4-en-17β-ol;</text>
              </clause> 
<clause id="H518ECAE3CB3F41AAB0D46A61440E0CC0" indent="paragraph">
                <enum>(lxxiv)</enum>
                <text>[3,2-c]pyrazole-5α-androstan-17β-ol; and</text>
              </clause>
              <after-quoted-block>; and</after-quoted-block>
            </quoted-block>
          </subparagraph>
        </paragraph> 
<paragraph id="H07693AB59818443CB3734CF754FB66E5">
          <enum>(2)</enum>
          <text>by adding at the end the following:</text> 
<quoted-block style="OLC" display-inline="no-display-inline" id="HFC5BB19B5C4543F6AA5450E594BAECB1"> 
<subparagraph id="HF81DD0EB56914B03BB4E06FE1E646F8D" indent="subsection">
              <enum>(C)</enum> 
<clause id="H04CE2141481A41909A2962144DFABD60" commented="no" display-inline="yes-display-inline">
                <enum>(i)</enum>
                <text>Subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Controlled Substances Act/s:102/p:41/sp:C/cl:ii" entity-type="act">clause (ii)</cato:entity-ref>, a drug or hormonal substance (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone) that is not listed in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/p:41/sp:A" entity-type="act">subparagraph (A)</cato:entity-ref> and is derived from, or has a chemical structure substantially similar to, 1 or more anabolic steroids listed in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/p:41/sp:A" entity-type="act">subparagraph (A)</cato:entity-ref> shall be considered to be an anabolic steroid for purposes of this Act if—</text> 
<subclause id="HE3B99B322DB1437CA6A098980DCD41E2" indent="subparagraph">
                  <enum>(I)</enum>
                  <text>the drug or substance has been created or manufactured with the intent of producing a drug or other substance that either—</text> 
<item id="HFE73AAE94E8D4DCA89E94AFA489ED337" indent="clause">
                    <enum>(aa)</enum>
                    <text>promotes muscle growth; or</text>
                  </item> 
<item id="HD6DDE17401154303AF2FE75121F96EDC" indent="clause">
                    <enum>(bb)</enum>
                    <text>otherwise causes a pharmacological effect similar to that of testosterone; or</text>
                  </item>
                </subclause> 
<subclause id="H7BA129A07FCE4E668005C2155222A481" indent="subparagraph">
                  <enum>(II)</enum>
                  <text>the drug or substance has been, or is intended to be, marketed or otherwise promoted in any manner suggesting that consuming it will promote muscle growth or any other pharmacological effect similar to that of testosterone.</text>
                </subclause>
              </clause> 
<clause id="HFC38C3C111734C33BE05C401F455C05C" indent="paragraph">
                <enum>(ii)</enum>
                <text>A substance shall not be considered to be a drug or hormonal substance for purposes of this subparagraph if it—</text> 
<subclause id="H8A528D30F3AF4044B0765668E8937047" indent="subparagraph">
                  <enum>(I)</enum>
                  <text>is—</text> 
<item id="HED37DD873B9C4616886373E07CEFB321" indent="clause">
                    <enum>(aa)</enum>
                    <text>an herb or other botanical;</text>
                  </item> 
<item id="H02B0C4C7E52849EDA04A73F00CFE4457" indent="clause">
                    <enum>(bb)</enum>
                    <text>a concentrate, metabolite, or extract of, or a constituent isolated directly from, an herb or other botanical; or</text>
                  </item> 
<item id="HFEE97B1D825A4B8CBF01CD8BC69D446A" indent="clause">
                    <enum>(cc)</enum>
                    <text>a combination of 2 or more substances described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Controlled Substances Act/s:102/p:41/sp:C/cl:ii/scl:I/i:aa" entity-type="act">item (aa)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Controlled Substances Act/s:102/p:41/sp:C/cl:ii/scl:I/i:bb" entity-type="act">(bb)</cato:entity-ref>;</text>
                  </item>
                </subclause> 
<subclause id="H08B57F7299BC436EA78F7EF043FFFE5E" indent="subparagraph">
                  <enum>(II)</enum>
                  <text>is a dietary ingredient for purposes of the <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                      <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act">Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/301">
                      <cato:entity-ref entity-type="uscode" value="usc/21/301/etseq">21 U.S.C. 301 et seq.</cato:entity-ref>
                    </external-xref>)</cato:entity>; and</text>
                </subclause> 
<subclause id="H41D7041D55FA4C65821E75B9294C602C" indent="subparagraph">
                  <enum>(III)</enum>
                  <text display-inline="yes-display-inline">is not anabolic or androgenic.</text>
                </subclause>
              </clause> 
<clause id="HCF313A1F84A64B659AD9C75CC00A2211" indent="paragraph">
                <enum>(iii)</enum>
                <text>In accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:515/p:a" entity-type="act">section 515(a)</cato:entity-ref>, any person claiming the benefit of an exemption or exception under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Controlled Substances Act/s:102/p:41/sp:C/cl:ii" entity-type="act">clause (ii)</cato:entity-ref> shall bear the burden of going forward with the evidence with respect to such exemption or exception.</text>
              </clause>
            </subparagraph>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
        </paragraph>
      </subsection> 
<subsection id="HF18AED7CE5EB473FAF90C645D4FB2F8B">
        <enum>(b)</enum>
        <header>Classification authority</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:201">Section 201 of the Controlled Substances Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/811">
            <cato:entity-ref entity-type="uscode" value="usc/21/811">21 U.S.C. 811</cato:entity-ref>
          </external-xref>)</cato:entity> is amended by adding at the end the following:</text> 
<quoted-block style="OLC" display-inline="no-display-inline" id="H7A9F6C19323F4492AB7F0EDA494ADDE5"> 
<subsection id="H9BB30F1DA98C43E0AC1244142122AD06">
            <enum>(i)</enum>
            <header>Temporary and permanent scheduling of recently emerged anabolic steroids</header> 
<paragraph id="H641D3062668146918D2FFD1F9128B73D">
              <enum>(1)</enum>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> may issue a temporary order adding a drug or other substance to the definition of anabolic steroids if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> finds that—</text> 
<subparagraph id="H2ACB05C0D27A4C5892538E87DD0C6623">
                <enum>(A)</enum>
                <text>the drug or other substance satisfies the criteria for being considered an anabolic steroid under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/ss:41" entity-type="act">section 102(41)</cato:entity-ref> but is not listed in that section or by regulation of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> as being an anabolic steroid; and</text>
              </subparagraph> 
<subparagraph id="H05D5DC2CD40344A6B1031E42FBB096A6">
                <enum>(B)</enum>
                <text display-inline="yes-display-inline">adding such drug or other substance to the definition of anabolic steroids will assist in preventing abuse or misuse of the drug or other substance.</text>
              </subparagraph>
            </paragraph> 
<paragraph id="H29B4A04BECBE4B3095325E5C00C1DD93">
              <enum>(2)</enum>
              <text>An order issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/ss:i/p:1" entity-type="act" proposed="true">paragraph (1)</cato:entity-ref> shall not take effect until 30 days after the date of the publication by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> of a notice in the Federal Register of the intention to issue such order and the grounds upon which such order is to be issued. The order shall expire not later than 24 months after the date it becomes effective, except that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> may, during the pendency of proceedings under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/ss:i/p:6" entity-type="act" proposed="true">paragraph (6)</cato:entity-ref>, extend the temporary scheduling order for up to 6 months.</text>
            </paragraph> 
<paragraph id="H3615C89A23C348C78AD810ACC5868FFC">
              <enum>(3)</enum>
              <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> shall transmit notice of an order proposed to be issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/ss:i/p:1" entity-type="act" proposed="true">paragraph (1)</cato:entity-ref> to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7500" entity-type="federal-body">Secretary of Health and Human Services</cato:entity-ref>. In issuing an order under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/ss:i/p:1" entity-type="act" proposed="true">paragraph (1)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> shall take into consideration any comments submitted by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7500" entity-type="federal-body">Secretary</cato:entity-ref> in response to a notice transmitted pursuant to this paragraph.</text>
            </paragraph> 
<paragraph id="HA0024484F5894475B5314350226AFBBF">
              <enum>(4)</enum>
              <text>A temporary scheduling order issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/ss:i/p:1" entity-type="act" proposed="true">paragraph (1)</cato:entity-ref> shall be vacated upon the issuance of a permanent scheduling order under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/ss:i/p:6" entity-type="act" proposed="true">paragraph (6)</cato:entity-ref>.</text>
            </paragraph> 
<paragraph id="H39721FC8418748029C7484ADD6F05548">
              <enum>(5)</enum>
              <text>An order issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/ss:i/p:1" entity-type="act" proposed="true">paragraph (1)</cato:entity-ref> is not subject to judicial review.</text>
            </paragraph> 
<paragraph id="HE22D7AE7B9BF4884A7AF95AFACB2E3F7">
              <enum>(6)</enum>
              <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> may, by rule, issue a permanent order adding a drug or other substance to the definition of anabolic steroids if such drug or other substance satisfies the criteria for being considered an anabolic steroid under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/ss:41" entity-type="act">section 102(41)</cato:entity-ref>. Such rulemaking may be commenced simultaneously with the issuance of the temporary order issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:102/ss:i/p:1" entity-type="act" proposed="true">paragraph (1)</cato:entity-ref>.</text>
            </paragraph>
          </subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
      </subsection>
    </section> 
<section id="H8CFC62AC998B4B7E9DD188DA8C017C26">
      <enum>3.</enum>
      <header>Labeling requirements</header> 
<subsection id="H9BF569951C5F409AB06D485D2B34CB6D">
        <enum>(a)</enum>
        <header>In general</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref value="Controlled Substances Act/s:305" entity-type="act">Section 305 of the Controlled Substances Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/825">
            <cato:entity-ref entity-type="uscode" value="usc/21/825">21 U.S.C. 825</cato:entity-ref>
          </external-xref>)</cato:entity> is amended by adding at the end the following:</text> 
<quoted-block style="OLC" display-inline="no-display-inline" id="HECF14BA2DE7A4935BE83FFB891E2BFBD"> 
<subsection id="H93CE492FACE14A38B8339104EB37B4AD">
            <enum>(e)</enum>
            <header>False Labeling of Anabolic Steroids</header> 
<paragraph id="H73174643E5464EFFA8C234DE7B26D918">
              <enum>(1)</enum>
              <text display-inline="yes-display-inline">It shall be unlawful to import, export, manufacture, distribute, dispense, or possess with intent to manufacture, distribute, or dispense, an anabolic steroid or product containing an anabolic steroid, unless the steroid or product bears a label clearly identifying an anabolic steroid or product containing an anabolic steroid by the nomenclature used by the International Union of Pure and Applied Chemistry (IUPAC).</text>
            </paragraph> 
<paragraph id="H93B24532904242D9A3064B347B210B0B" commented="no">
              <enum>(2)</enum> 
<subparagraph id="HBED11304AEA04E45B62C2E12BCE2A6B4" commented="no" display-inline="yes-display-inline">
                <enum>(A)</enum>
                <text display-inline="yes-display-inline">A product described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:305/ss:e/p:2/sp:B" entity-type="act" proposed="true">subparagraph (B)</cato:entity-ref> is exempt from the International Union of Pure and Applied Chemistry nomenclature requirement of this subsection if such product is labeled in the manner required under the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act">Federal Food, Drug, and Cosmetic Act</cato:entity-ref>.</text>
              </subparagraph> 
<subparagraph id="H54D459F42B254216AF013DD160E1735E" indent="up1" commented="no">
                <enum>(B)</enum>
                <text>A product is described in this subparagraph if the product—</text> 
<clause id="H55F6C561DF1F413788C71A580303BE27" commented="no">
                  <enum>(i)</enum>
                  <text>is the subject of an approved application as described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:b">section 505(b)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j" entity-type="act">(j) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>; or</text>
                </clause> 
<clause id="H744840E54DD5464EB62277461697555B" commented="no">
                  <enum>(ii)</enum>
                  <text>is exempt from the provisions of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Federal Food, Drug, and Cosmetic Act/s:505" entity-type="act">section 505</cato:entity-ref> of such Act relating to new drugs because—</text> 
<subclause id="H4BA07926DA10447C8B9FA93309E6BEDD" commented="no">
                    <enum>(I)</enum>
                    <text>it is intended solely for investigational use as described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:i">section 505(i) of such Act</cato:entity-ref>; and</text>
                  </subclause> 
<subclause id="HB000C994FFA14FDD81C27DC7F184C1B3" commented="no">
                    <enum>(II)</enum>
                    <text>such product is being used exclusively for purposes of a clinical trial that is the subject of an effective investigational new drug application.</text>
                  </subclause>
                </clause>
              </subparagraph>
            </paragraph>
          </subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
      </subsection> 
<subsection id="HCAE47999B3024DB48C6F01E20878801C">
        <enum>(b)</enum>
        <header>Clarification to Import and Export statute</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref value="Controlled Substances Act/s:1010" entity-type="act">Section 1010 of the Controlled Substances Import and Export Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/960">
            <cato:entity-ref entity-type="uscode" value="usc/21/960">21 U.S.C. 960</cato:entity-ref>
          </external-xref>)</cato:entity> is amended, in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:1010/ss:a/p:1" entity-type="act">subsection (a)(1)</cato:entity-ref>, by inserting <quote>
            305,</quote> before <quote>
            1002
          </quote>.</text>
      </subsection> 
<subsection id="HAED1492D84334644A579854219B97762">
        <enum>(c)</enum>
        <header>Civil penalties</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref value="Controlled Substances Act/s:402" entity-type="act">Section 402 of the Controlled Substances Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/842">
            <cato:entity-ref entity-type="uscode" value="usc/21/842">21 U.S.C. 842</cato:entity-ref>
          </external-xref>)</cato:entity> is amended—</text> 
<paragraph id="H3703E5FCF5A64940A93CDB1752EFE085">
          <enum>(1)</enum>
          <text display-inline="yes-display-inline">in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:402/ss:a" entity-type="act">subsection (a)</cato:entity-ref>—</text> 
<subparagraph id="H5DD46699E82E476A9B487E068496C6B9">
            <enum>(A)</enum>
            <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:402/ss:a/p:14" entity-type="act">paragraph (14)</cato:entity-ref>, by striking <quote>or</quote> at the end;</text>
          </subparagraph> 
<subparagraph id="HAF4AD37388EA4E2396EB54525B3240C3">
            <enum>(B)</enum>
            <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:402/ss:a/p:15" entity-type="act">paragraph (15)</cato:entity-ref>, by striking the period at the end and inserting <quote>; or</quote>; and </text>
          </subparagraph> 
<subparagraph id="HA49B307F8E3F4C1DB5E5FD893C98EE19">
            <enum>(C)</enum>
            <text>by inserting, after <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:402/ss:a/p:15" entity-type="act">paragraph (15)</cato:entity-ref>, the following:</text> 
<quoted-block style="OLC" display-inline="no-display-inline" id="HED92EE21056546148BE668827F0B6E29"> 
<paragraph id="H3CB5C3EE65A94244B4E7196B12681B87">
                <enum>(16)</enum>
                <text display-inline="yes-display-inline">to violate <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:305/ss:e" entity-type="act" proposed="true">subsection (e) of section 305 of the Controlled Substances Act</cato:entity-ref>.</text>
              </paragraph>
              <after-quoted-block>; and</after-quoted-block>
            </quoted-block>
          </subparagraph>
        </paragraph> 
<paragraph id="HE5B26DBABAF14F79883DCE72BC8ACA40">
          <enum>(2)</enum>
          <text display-inline="yes-display-inline">in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:402/ss:c/p:1" entity-type="act">subsection (c)(1)</cato:entity-ref>—</text> 
<subparagraph id="HA61D508DC37C4AF68034A99565040FC1">
            <enum>(A)</enum>
            <text display-inline="yes-display-inline">by inserting, in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:402/ss:c/p:1/sp:A" entity-type="act">subparagraph (A)</cato:entity-ref>, after <quote>
                subparagraph (B)
              </quote> the following: <quote>, (C), or (D)
              </quote>; and</text>
          </subparagraph> 
<subparagraph id="H1030A8E7022C4C89A305D76C3D012A8A">
            <enum>(B)</enum>
            <text>by inserting after <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:402/ss:c/p:1/sp:B" entity-type="act">subparagraph (B)</cato:entity-ref> the following: </text> 
<quoted-block style="OLC" display-inline="no-display-inline" id="H3C85762BD7E640EB956AF42B725FCA22"> 
<subparagraph id="HCAB14273B86248C1B915CBFEBEAFA087" indent="subsection">
                <enum>(C)</enum>
                <text display-inline="yes-display-inline">In the case of a violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:402/ss:a/p:16" entity-type="act" proposed="true">paragraph (16) of subsection (a)</cato:entity-ref> of this section by an importer, exporter, manufacturer, or distributor (other than as provided in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:402/ss:c/p:1/sp:D" entity-type="act" proposed="true">subparagraph (D)</cato:entity-ref>), up to $500,000 per violation. For purposes of this subparagraph, a violation is defined as each instance of importation, exportation, manufacturing, distribution, or possession with intent to manufacture or distribute, in violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:402/ss:a/p:16" entity-type="act" proposed="true">paragraph (16) of subsection (a)</cato:entity-ref>.</text>
              </subparagraph> 
<subparagraph id="HD7AD338646174761835B839085BE1E0A" indent="subsection">
                <enum>(D)</enum>
                <text display-inline="yes-display-inline">In the case of a distribution, dispensing, or possession with intent to distribute or dispense in violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:402/ss:a/p:16" entity-type="act" proposed="true">paragraph (16) of subsection (a)</cato:entity-ref> of this section at the retail level, up to $1000 per violation. For purposes of this paragraph, the term <quote>at the retail level</quote> refers to products sold, or held for sale, directly to the consumer for personal use. Each package, container or other separate unit containing an anabolic steroid that is distributed, dispensed, or possessed with intent to distribute or dispense at the retail level in violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Controlled Substances Act/s:402/ss:a/p:16" entity-type="act" proposed="true">paragraph (16) of subsection (a)</cato:entity-ref> shall be considered a separate violation. </text>
              </subparagraph>
              <after-quoted-block>.</after-quoted-block>
            </quoted-block>
          </subparagraph>
        </paragraph>
      </subsection>
    </section> 
<section id="H28244B815352468E8C821EBFEF6156DE">
      <enum>4.</enum>
      <header>Identification and publication of list of products containing anabolic steroids</header> 
<subsection id="HF18612CE54CA4B1BB58AD01A7C2BF248">
        <enum>(a)</enum>
        <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> may, in his discretion, collect data and analyze products to determine whether they contain anabolic steroids and are properly labeled in accordance with this section. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> may publish in the Federal Register or on the website of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1524" entity-type="federal-body">Drug Enforcement Administration</cato:entity-ref> a list of products that he has determined, based on substantial evidence, contain an anabolic steroid and are not labeled in accordance with this section.</text>
      </subsection> 
<subsection id="HB9B321A069B34BE685CD2FC7A3109881">
        <enum>(b)</enum>
        <text display-inline="yes-display-inline">The absence of a product from the list referred to in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Designer Anabolic Steroid Control Act of 2014/s:4/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall not constitute evidence that the product does not contain an anabolic steroid.</text>
      </subsection>
    </section> 
</legis-body>
<endorsement display="yes">
<action-date date="20140915">September 15, 2014</action-date>
<action-desc>Reported from the Committee on <committee-name committee-id="HIF00" added-display-style="italic" deleted-display-style="strikethrough">Energy and Commerce</committee-name> with an amendment</action-desc>
<action-date date="20140915">September 15, 2014</action-date>
<action-desc>Reported from the <committee-name committee-id="HJU00">Committee on the Judiciary</committee-name> with an amendment; committed to the Committee of the Whole House on the State of the Union and ordered to be printed</action-desc>
  </endorsement>
</bill>
</doc>